CD8A and neoplasm: Biomarker data obtained from the phase 1b portion of the trial (n = 21) suggested that, in addition to the observed ORR of 61.9%, the combination of T-VEC and pembrolizumab favorably altered the tumor microenvironment and contributed to systemic anti-tumor effects (e.g., an increase in circulating and intratumoral CD8+ T cells).3